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ABSTRACT 
 
Introduction: Burning Mouth Syndrome (BMS) is a rare disease of unknown origin. No efficient treatment is 
known, and integrative approaches are warranted. So far, individualized homeopathy (iHOM) has not been 
evaluated or reported in peer-reviewed journal as a treatment option. 
Method: At a centre of complementary medicine at a University institute in Switzerland, a 38-year old patient 
with BMS and various comorbidities has been treated with (iHOM) between July 2014 and August 2018. The 
treatment is characterized by the prescription of individually selected homeopathic single remedies. During 
follow-up visits, outcome was assessed with two validated questionnaires concerning patient reported outcomes. 
In order to assess whether the documented changes are likely to be associated with the homeopathic intervention, 
an assessment using the modified Naranjo-criteria was performed. 
Results: Over an observation period of four years, an increasingly beneficial result from iHOM was noted for oral 
dysesthesia and pains as well as for the concomitant symptoms.  
Conclusion: Considering the multi-factorial aetiology of BMS, a therapeutic approach like iHOM which integrates 
the completeness of symptoms and complaints of a patient might be of value in cases where an association of 
psychological factors and the neuralgic complaints is likely.  
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INTRODUCTION 
Patients with sore, burning, tingling or numb parts of the oral cavity are classified as having Burning Mouth 
Syndrome (BMS), when the oral examination is normal (1) and there are no secondary causes for the presenting 
symptoms (2). Primary BMS is a rare disease with an incidence ranging from 0.01-0.1% of the general 
population, with the highest incidence in postmenopausal women above 70 years of age (3). To date, origin and 
pathogenesis of BMS remain unknown. Mostly aetiology is referred to as multifactorial, though a neuropathic 
pathway involving the trigeminal nerve, chorda tympani and glossopharyngeal nerve is favoured (4-6). 
Psychological and personality factors may be linked to the occurrence of BMS as well (7). There are currently 
no universally accepted guidelines for managing BMS and in a recent literature review and meta-analysis, the 
results of various treatment options yielded a significant benefit over placebo concerning pain scores (8). 
Further, despite several therapeutic approaches it was found in a retrospective analysis of 48 women that the 
course of the disease varies from spontaneous complete remission (3%) to no improvement in close to 70% of 
the patients after five years (9). The authors conclude that new, safe and efficacious treatment options should be 
developed. As multiple factors are linked in the development and evolution of BMS, a complex and flexible 
treatment approach is favoured (1).  
Concerning complementary medicine, a systematic review and meta-analysis on the use of Hypericum 
perforatum in dentistry reports about one randomized placebo-controlled trial (RCT) concerning herbal 
treatment in patients with BMS (10). Pain relief was not significant, but number of painful sites was reduced 
significantly. Further, there exists a Master’s thesis analysing a homeopathic approach, Arsenicum album (Ars-
a) 6X daily, for symptom management of BMS in a RCT. In this study 31 patients with different amount of 
comorbidities and different duration of symptoms were evaluated. After 90 days, oral burning in the verum 
group (n=16) improved significantly when compared to placebo (n=15). However, the symptoms persisted in 28 
patients and concomitant symptoms were not addressed by the use of Arsenicum album 6X (11). In a second, 
open phase the patients received individualized Homeopathy (iHOM) and experienced a global improvement, 
including associated symptoms, such as depression, anxiety or gastrointestinal disorders. Considering this, it 
seems reasonable to present and discuss a detailed case report of long-lasting BMS using iHOM, an approach so 
far unestablished in the treatment for BMS.  
 
PATIENT INFORMATION 
The female, 38 year old patient was treated at the Institute of Complementary and Integrative Medicine (IKIM) 
University of Bern, Switzerland. In July 2014 she was referred by the department of aneasthesiology and pain 
medicine, Bern University Hospital where a BMS was diagnosed three years ago. Differential diagnoses were 
excluded from the referring clinic. At time of consultation, other concomitant symptoms were a moderate 
depression (assessed by the Beck Inventory Depression score), dysmenorrhea, overweight (Body Mass Index 
25–30 kg/m2) and unspecific muscular pains which were suspected for being fibromyalgia. At the first 
consultation she reported daily constant burning and/or numbness of the left side of her tongue and the back of 
her throat. She also complained of insomnia, fatigue, dysmenorrhea and chronic muscle pains. For BMS-
symptoms, she had tried Alpha lipoic acid, Pregabalin, Gabapentin, Venlaflaxin and topical Clonazepam as well 
as capsaicin, buprenorphine injections in the superior cervical ganglion, acupuncture and removal of all 
amalgam without any result. Since the start of her symptoms, she was also visiting a psychiatrist on regular 
basis, but she felt that this had no effect. Currently she was taking 50mg Chlorprothixen (Truxal), Thiamine and 
two herbal products (a valerian and hop combi-preparation and St. John’s wort). Besides, she received hormonal 
injections every three months for contraception and took pain killers for the muscle and tissue pains. 
 
CLINICAL FINDINGS 
The patient presented herself with slow and sluggish speech as well as reduced facial mimic and needed to suck 
lozenges all day long, as this gave her relieve for dysesthesia in her oral cavity. In the anamnesis it was found, 
that BMS started after the intake of several drugs she had received for a post-partum depression after the birth of 
the patients’ son, who was, by that time, four years old. She reported that she needed to change the anti-depressive 
therapy many times due to side-effects and that she couldn’t remember after what particular drug or when exactly 
the symptoms of BMS began. Apart from numbness and burning of the tongue, she complaint of a salty or bitter 
taste in her mouth, which was ameliorated while eating. She considered this the reason why she needed to eat 
constantly. She had problems falling asleep, felt tired and without motivation during the day ever since the 
delivery of her child. Thus, she had never been able to take care of her son herself, but needed to rely on her 
husband and neighbours. Moreover, she became very irritated by him and struck him, when she was alone with 
him. Therefore, the family needed a nursemaid in order to provide the child’s safety. Since the birth of her son, 
she also lost all her libido and over the past four years, she never had sexual intercourse with her husband. Around 
three months before the consultation at IKIM, pains in all her extremities started and had been suggested for being 
fibromyalgia from her primary care doctor. They were better from physical exercise, but she mostly felt too tired 
to exercise. The dysmenorrhea had been present since her menarche and responded sometimes to hormonal 
treatment.  
 
THERAPEUTIC INTERVENTION 
The doctor at IKIM, who treated the patient, is trained in general medicine and holds a diploma for iHOM, a term 
which refers to individually administered homeopathic prescriptions of a single remedy, selected after a process 
of matching the present symptoms of the patient with those described in the homeopathic medicines’ textbook 
“Materia Medica” following the „Law of Similars” (12). For the treatment of this case only highly diluted and 
succussed, i.e. so-called potentized homeopathic remedies were used. In particular, ‘C-Potencies’, in which the 
original substance is diluted 1:100, followed by 10 succussions were prescribed in single doses of 1x5 globules 
sublingualy or in 500ml tab water to be sipped throughout the day (liquid dilution) and ‘Q-Potencies’, in which 
the original substance is diluted 1:50’000, followed by 2-10 succussions were prescribed in a dosage of 3 drops 
in 100ml tab water daily. The number of the potency (e.g. 30, 200 or 3, 5 respectively) indicates the number of 
repetitions of this process. Two pharmacies, either Spagyros® (13) or Schmidt-Nagel® (14), approved by the 
Swiss Agency for Therapeutic Products (Swissmedic), provided the homeopathic remedies. They were prepared 
following the instruction of the European Pharmacopoeia, Monograph 1038 and 2045 and the Homeopathic 
Pharmacopoeia (HAB 5.2.2-5.2.6). For the homeopathic evaluation, the totality of presenting symptoms was 
considered and the practitioner edition of Complete Dynamics repertory © (15) was used.  
Jurisdiction of the Ethics Committee of the Canton Bern was obtained and informed consent was given by the 
patient. The reporting is consistent with the HOM-CASE guidelines for reporting cases with homeopathic 
interventions ((16); Supplementary file 1) 
 
The initial evaluation of the case is shown in table 1. It pointed to the remedy Sepia, which was prescribed as a 
single dose of C200 potency (13). The patient was also instructed to start with a Q3-potency (13) of the same 
remedy, if there was no result after two weeks. Changes of potencies and remedies are described in the section on 
follow-up and outcomes. Following a method described by Kent, the C-potency was risen, when the desired effect 
subsided (17). Additionally, Q-potencies were given for the relief of local symptoms, which aggravated after the 
C-Potency (17; Chapter 36). 
 
FOLLOW-UP AND OUTCOMES 
During the observation time the patient was asked  to answer subjective outcome-assessments forms (Measure 
Yourself Medical Outcome Profile – MYMOP; (18). They were revised and summarised for the case-
documentation, along with the notes of the treating doctor. Additionally, the subject was asked to assess the 
treatment outcome retrospectively in a validated questionnaire on Outcome Related to Impact on Daily Living 
(ORIDL; (19) in November 2017. The English assessment forms were translated by the treating doctor into 
German for patients’ convenience.  
Follow-up consultations initially took place every three to six weeks and were expanded up to every five months 
later, corresponding to the clinical improvement. After a relapse, the frequency of the visits needed to be reduced 
for a while and is currently being increased again. An outline of the consultations along with the given treatment 
and the assessed symptoms (18) is shown in table 2. In detail, the patient reported in the beginning rather an 
increase of the BMS-symptoms, but she felt generally better: she had more energy and less muscular pains from 
the first dose onwards. There also was immediately a marked improvement in the relationship with her son: she 
didn’t need to strike him anymore and two months after the start of iHOM she was able to take care about him 
alone. Further, she reduced the Chlorproxithen to half. As the symptoms of the BMS appeared worse, the Q3 
potency was stopped, but this didn’t help. When she had a relapse of the emotional symptoms, the homeopathic 
dilution was risen and Sepia C1000 (12; liquid dilution) in September 2014 and end of September 2014 Sepia Q5 
(13) was started. End of October she reported a slight improvement of the burning mouth with persistent improve 
of the mental features. As no further change could be noted and the salty taste in the mouth had increased, an 
intermediate dose of Natrium muriaticum C200 (13) was prescribed in November. This remedy is known in the 
homeopathic textbooks for being a complement to Sepia. After a short improvement a relapse of all symptoms to 
the state of September occurred and the therapy was changed back to Sepia in January 2015. This time, C30 (13) 
was given repeatedly (first daily, then once per week) and burning and numbness diminished considerably. By 
October of the same year there was only minor burning left on some days of the week. By this time she had 
reduced Chlorproxithen to 2,5 mg daily and stopped the herbal treatment. The treatment was changed again to Q-
potencies (13), which were raised every 3 weeks by two potencies. End of 2015 she did not need painkillers 
anymore and had weaned of all medication completely. She was now fully able to manage the household and 
performed well with her son. Alongside, she joined a program for losing weight and reported to have gained 
interest in live again. However, by the time the BMS was under control she developed unspecific vertigo (normal 
physical examinations) and since the beginning of iHOM her dysmenorrhea had become worse, so that she 
changed the anti-contraceptive therapy at several times. In march 2016, after she had changed to a certain anti-
baby pill, she had pronounced metrorrhagia along with increased fatique and vertigo. She was given Ammonium 
muriaticum Q5 (13), but this didn’t bring any change. The metrorrhagia stopped after she changed back to a 
hormonal depot-injection and the homeopathic treatment with Sepia Q (13) was re-established. After the Q19-
potency there was a relapse of symptoms of all planes and she was given one dose of Sepia C30 (14) again and 
was told to take Sepia Q15 once every time the BMS-symptoms were prominent. This, and an increase of the 
potency to C200 (14) as well as an attempt with the remedy Nux-vomica (13) did not bring any result. As all 
symptoms still matched the symptoms described for Sepia in the ‘Materia Medica’, she received Sepia XM (14; 
liquid dilution) in March 2017 followed by Lactose without any homeopathic substance (Placebo). Also, Sepia 
Q5 (13) was given to be taken once in case of a burning tongue. Symptoms slowly improved, so that in June 2017 
again nearly all symptoms but the dysesthesia in the mouth were gone. She reported in September 2017, that she 
had been well and with less BMS-symptoms until end of august and then the complaints relapsed. Another dose 
of Sepia XM (14; liquid dilution) followed by placebo was prescribed. In November 2017 the patient was nearly 
free of any complaints. She also reported, that she and her husband have been intimate for the first time since the 
birth of her son. 
In the ORIDL-evaluation (19) she rated major improvement for the main complaint, the overall coping with the 
problem and the general well-being. From November 2017 onwards, there was no further change in the treatment 
or the severity of complaints. Sometimes, when the patient is not occupied or when she gets angry, she still has 
some minor discomfort in the mouth. It responds, however, always to a dose of Sepia Q15 (13). 
Additionally, the modified Naranjo-criteria were used in order to assess the likely-hood of the documented 
changes being associated with the homeopathic intervention, as suggested in the HOM-CASE guidelines 
(QUOTE). The agreed score was 10 of 13 points (Supplementary file 2).  
 
DISCUSSION 
There are various treatment options for BMS, but they yield robust results consisting in a significant reduction of 
pain-scores in meta-analysis (8). Concerning alternatives, such as homeopathic treatment, limited data suggests 
that the homeopathic remedy Ars-a 6X, taken on a daily basis, may help for symptom relief when compared to 
placebo, but the actual changes in pain scores were small (Chebel). The prognosis of this disease is variable and 
there exist cases of complete spontaneous regression (9). Further, BMS is often associated with psychological 
distress (7) and Sardella et a. found, that the patients with spontaneous regressions also experienced profound 
psychological changes (9). In the open phase of the mentioned study on Ars-a 6X, 28 patients seemed to undergo 
such changes under the treatment with iHOM, which followed the randomized phase with Ars-a 6X. The here 
presented patient reported an improvement of mood, energy and drive as well as other mental factors as well. 
appeared prior to the amelioration of the complaints of BMS, an effect which is stated to be associated with iHOM 
(16). For being a single case report, no conclusions about the influence of iHOM on the psychological factors can 
be drawn. However, there are certain coincidences which make an effect from the homeopathic remedy likely: 
Firstly, Sepia, as a homeopathic remedy is known for post-partum psychosis, hormonal dysregulation with loss 
of libido, general weakness with amelioration by movement and aggressive behaviour towards the own children. 
All of the symptoms were present in this case, and most of them were changing throughout the evolution of the 
patient. Secondly, there was an aggravation of BMS-symptoms and dysmenorrhea along with an amelioration of 
behaviour and drive in the beginning of the treatment: a situation which is unlikely to occur spontaneously. 
Thirdly, every time when the patient reported a relapse of symptoms, the indicated homeopathic remedy was 
repeated or the potency was risen and the symptoms reduced consecutively. Further, sometimes the amelioration 
of the patient’s symptoms only responded to the higher potency, but not after the attempt of a repetition of the 
same potency. On the other hand, there exist a number of confounders, which limit the confidence in the observed 
result. Firstly, spontaneous regression is not excluded, even though BMS-symptoms existed for more than two 
years. Secondly, iHOM as an additional intervention could have been psychologically supportive as such and the 
remedy may not have had a specific effect. Lastly, other life-events may also have contributed to the improvement. 
Still, in the Naranjo-assessment two aspects considered to be attributed to iHOM, ‘Did symptoms improve in the 
opposite order of the development of the disease’ and ‘Did at least one of the aspects of ‘Hering’s law of cure’ 
apply to the case’, were present and the score was considerably high (Supplementary file 2).  
Besides the slightly increased oral burning, we observed no undesirable effects of the prescribed remedy, which 
could be managed with a change of potency. This event can regarded as an homeopathic aggravation as classified 
by Stub et al. (20) and the latter were graduated grade I according to the common terminology criteria for adverse 
effects CTCAE in a meta-analysis (21, 22). Thus, iHOM did not have safety-concerns in this case. 
The limited experience of the presented case and the observations from Chebel (11), iHOM seems to support 
multi-dimensional recovery. This global effect of iHOM was also observed in cancer patients by Frass and 
colleagues: patients randomized to additional iHOM experienced significant improvement of general well-being 
as well as pain when compared to a cohort without this additional treatment (23).  
As BMS is often associated with psychological distress (7), results of two RCT’s on depression (24, 25) may also 
support a possible effect of iHOM in the treatment of BMS. In these studies, iHOM was equivalent to Fluoxetin 
in moderate and severe depression.  
To sum up, an interdisciplinary approach for the treatment of BMS is favoured (26) and iHOM should be evaluated 
as one additional part of such an approach (26). As presented in this case, it may be considered as a safe treatment-
option in cases refractory to other therapies. If considered, the patient should be referred to a specialist for iHOM. 
 
CONCLUSION 
This case shows how iHOM integrates the completeness of symptoms and complaints of a patient in the treatment 
approach. Considering the multi-factorial aetiology of BMS, iHOM might be of value in cases where an 
association of psychological factors and the neuralgic complaints is likely. 
 
  
List of abbreviations 
 
Ars-a  Arsenicum album 
BMS  Burning mouth syndrome 
iHOM  Individualized homeopathy 
IKIM  Institute of Complementary and Integrative Medicine, University of Bern 
MYMOP Measure Yourself Medical Outcome Profile – Questionaire 
ORIDL  Outcome Related to Impact on Daily Living – Questionaire 
 
 
Declarations 
 
Acknowledgments 
To Dr. Andreas Siegenthaler and the patient  
Conflict of interest 
None to declare 
Availability of Data and Materials 
Data of this report is confidential. Anonymised material can be obtained from the author. 
Ethics approval and consent to participate 
Jurisdiction of the Ethics Committee of the Canton Bern was obtained with the Request ID 2017-00848 after the 
agreement of the patient, that the coded case data will be summarized and evaluated.  
Consent for publication 
Informed consent for publication was given by the patient. The signed document is confidential. 
Funding 
No funding was obtained for this case report and the preparation of the manuscript 
Authors' contributions 
Dr. med. K. Gaertner is responsible for data documentation and the preparation of the manuscript. Dr.med. M. 
Frei-Erb supervised the first author and added to the manuscript. 
. 
 
  
REFERENCES 
1. Evans RW, Drage LA. Burning mouth syndrome. Headache. 2005;45(8):1079-1081. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/16109125. 
2. Steele JC. The practical evaluation and management of patients with symptoms of a sore burning mouth. 
Clin Dermatol. 2016;34(4):449-457. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27343959. 
3. Kohorst JJ, Bruce AJ, Torgerson RR, Schenck LA, Davis MD. The prevalence of burning mouth 
syndrome: a population-based study. Br J Dermatol. 2015;172(6):1654-1656. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/25495557. 
4. Forssell H, Jääskeläinen S, Tenovuo O, Hinkka S. Sensory dysfunction in burning mouth syndrome. 
Pain. 2002;99(1):41-47. 
5. Grushka M, Ching V, Epstein J. Burning mouth syndrome. Adv Otorhinolaryngol. 2006;63:278-287. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/16733345. 
6. Jaaskelainen SK. Pathophysiology of primary burning mouth syndrome. Clin Neurophysiol. 
2012;123(1):71-77. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22030140. 
7. Galli F, Lodi G, Sardella A, Vegni E. Role of psychological factors in burning mouth syndrome: A 
systematic review and meta-analysis. Cephalalgia. 2017;37(3):265-277. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/27121358. 
8. Liu YF, Kim Y, Yoo T, Han P, Inman JC. Burning mouth syndrome: a systematic review of treatments. 
Oral Dis. 2018;24(3):325-334. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28247977. 
9. Sardella A, Lodi G, Demarosi F, Bez C, Cassano S, Carrassi A. Burning mouth syndrome: a retrospective 
study investigating spontaneous remission and response to treatments. Oral Dis. 2006;12(2):152-155. Available 
from: https://www.ncbi.nlm.nih.gov/pubmed/16476036. 
10. Raak C, Bussing A, Gassmann G, Boehm K, Ostermann T. A systematic review and meta-analysis on 
the use of Hypericum perforatum (St. John's Wort) for pain conditions in dental practice. Homeopathy. 
2012;101(4):204-210. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23089215. 
11. Chebel IFO. Ação do tratamento homeopático na sintomatologia da síndrome da ardência bucal em duas 
fases: estudo duplo cego placebo controlado e estudo aberto.  [Action of the homeopathic treatment in the 
symptoms of oral burning syndrome in two phases: double-blind placebo-controlled study and open study]. Sao 
Paolo: University of Sao Paolo; 2013. 
12. Hahnemann S. Organon der Heilkunst. [Hahnemann’s Organon of Medicine]. Standard edition of 6th 
ed. Schmidt JM, editor. Heidelberg: Haug; 1996/1999. 388 p. 
13. Spagyros AG, Neufeldstrasse 1, CH-3076 Worb, Switzerland. . 
14. Laboratoire homéopathique Schmidt-Nagel SA. Rue du Pré-Bouvier 27, CH-1217 Meyrin, Switzerland.  
15. Complete Dynamics, copyright Eduard van Grimsen. Based on Complete Repertory, copyright Roger 
van Zandvoort. Practitioner edition ed. [Accessed 2013-2018]. 
16. van Haselen RA. Homeopathic clinical case reports: Development of a supplement (HOM-CASE) to the 
CARE clinical case reporting guideline. Complement Ther Med. 2016;25:78-85. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/27062953. 
17. Kent JT. Lectures on Homoeopathic Philosophy. 7th ed. New Delhi: BJain; 2018. 342 p. 
18. Paterson C. Measuring outcomes in primary care: a patient generated measure, MYMOP, compared with 
the SF-36 health survey. Bmj. 1996;312(7037):1016-1020. 
19. Reilly D, Mercer SW, Bikker AP, Harrison T. Outcome related to impact on daily living: preliminary 
validation of the ORIDL instrument. BMC Health Serv Res. 2007;7:139. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/17764574. 
20. Stub T, Kristoffersen AE, Alraek T, Musial F, Steinsbekk A. Risk in homeopathy: Classification of 
adverse events and homeopathic aggravations--A cross sectional study among Norwegian homeopath patients. 
Complement Ther Med. 2015;23(4):535-543. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26275646. 
21. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events 
v5.0 (CTCAE). National Institutes of Health: National Cancer Institute.,  (2017). Available from: 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.p
df. [Accessed 15 May 2019]. 
22. Stub T, Musial F, Kristoffersen AA, Alraek T, Liu J. Adverse effects of homeopathy, what do we know? 
A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2016;26:146-
163. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27261996. 
23. Frass M, Friehs H, Thallinger C, Sohal NK, Marosi C, Muchitsch I, et al. Influence of adjunctive classical 
homeopathy on global health status and subjective wellbeing in cancer patients - A pragmatic randomized 
controlled trial. Complement Ther Med. 2015;23(3):309-317. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/26051564. 
24. Macias-Cortes Edel C, Llanes-Gonzalez L, Aguilar-Faisal L, Asbun-Bojalil J. Individualized 
homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women 
(HOMDEP-MENOP study): a randomized, double-dummy, double-blind, placebo-controlled trial. PLoS One. 
2015;10(3):e0118440. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25768800. 
25. Adler UC, Paiva NM, Cesar AT, Adler MS, Molina A, Padula AE, et al. Homeopathic Individualized Q-
Potencies versus Fluoxetine for Moderate to Severe Depression: Double-Blind, Randomized Non-Inferiority 
Trial. Evid Based Complement Alternat Med. 2011;2011:520182. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/19687192. 
26. Coculescu EC, Coculescu BI. Burning mouth syndrome: a review on diagnosis and treatment. J Med 
Life. 2014;7(4):512-514. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316128/. 
 
